Eagle Asset Management Inc. Makes New $2.19 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Eagle Asset Management Inc. purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 35,630 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,189,000.

Several other large investors have also recently modified their holdings of ANIP. Texas Permanent School Fund Corp lifted its stake in shares of ANI Pharmaceuticals by 1.3% in the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company’s stock worth $852,000 after acquiring an additional 178 shares during the period. Louisiana State Employees Retirement System lifted its position in shares of ANI Pharmaceuticals by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock worth $490,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System boosted its stake in shares of ANI Pharmaceuticals by 4.7% in the 2nd quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after purchasing an additional 211 shares during the last quarter. Simplicity Wealth LLC boosted its stake in shares of ANI Pharmaceuticals by 3.5% in the 2nd quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in shares of ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after buying an additional 233 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 3.0 %

Shares of NASDAQ:ANIP opened at $58.64 on Tuesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The business’s 50 day simple moving average is $58.31 and its two-hundred day simple moving average is $60.89. The firm has a market cap of $1.23 billion, a P/E ratio of -106.62 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. ANI Pharmaceuticals’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period last year, the business earned $1.05 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on ANIP. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Raymond James raised their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.